Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2015, Article ID 507349, 6 pages
http://dx.doi.org/10.1155/2015/507349
Research Article

The Effect of Xuefuzhuyu Oral Liquid on Aspirin Resistance and Its Association with rs5911, rs5787, and rs3842788 Gene Polymorphisms

1Cardiovascular Center, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China
2Physical Examination Center, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China
3Clinical Laboratory, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266033, China

Received 15 May 2015; Revised 3 August 2015; Accepted 11 August 2015

Academic Editor: Lay Kek Teh

Copyright © 2015 Mei Xue et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. M. Sweeny, D. A. Gorog, and V. Fuster, “Antiplatelet drug ‘resistance’. Part 1: mechanisms and clinical measurements,” Nature Reviews Cardiology, vol. 6, no. 4, pp. 273–282, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Yusuf, F. Zhao, S. R. Mehta, S. Chrolavicius, G. Tognoni, and K. K. Fox, “Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation,” The New England Journal of Medicine, vol. 345, no. 7, pp. 494–502, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. S. R. Steinhubl, P. B. Berger, J. Tift Mann III et al., “Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial,” The Journal of the American Medical Association, vol. 288, no. 19, pp. 2411–2420, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. E. A. Amsterdam, N. K. Wenger, R. G. Brindis et al., “2014 AHA/ACC Guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American college of cardiology/American heart association task force on practice guidelines,” Circulation, vol. 130, no. 25, pp. 2354–2394, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Szczeklik, J. Musiał, A. Undas, and M. Sanak, “Aspirin resistance,” Journal of Thrombosis and Haemostasis, vol. 3, no. 8, pp. 1655–1662, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. P. J. Gandhi and J. A. Cambria-Kiely, “Aspirin resistance and genetic polymorphisms,” Journal of Thrombosis and Thrombolysis, vol. 14, no. 1, pp. 51–58, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. A. O. Maree, R. J. Curtin, A. Chubb et al., “Cyclooxygenase-1 haplotype modulates platelet response to aspirin,” Journal of Thrombosis and Haemostasis, vol. 3, no. 10, pp. 2340–2345, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. Z.-H. Xu, J.-R. Jiao, R. Yang, B.-Y. Luo, X.-F. Wang, and F. Wu, “Aspirin resistance: clinical significance and genetic polymorphism,” Journal of International Medical Research, vol. 40, no. 1, pp. 282–292, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. X.-L. Li, J. Cao, L. Fan et al., “Genetic polymorphisms of HO-1 and COX-1 are associated with aspirin resistance defined by light transmittance aggregation in Chinese Han patients,” Clinical and Applied Thrombosis/Hemostasis, vol. 19, no. 5, pp. 513–521, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. E. Papp, V. Havasi, J. Bene et al., “Glycoprotein IIIA gene (PlA) polymorphism and aspirin resistance: is there any correlation?” Annals of Pharmacotherapy, vol. 39, no. 6, pp. 1013–1018, 2005. View at Google Scholar
  11. B. Pamukcu, H. Oflaz, and Y. Nisanci, “The role of platelet glycoprotein IIIa polymorphism in the high prevalence of in vitro aspirin resistance in patients with intracoronary stent restenosis,” The American Heart Journal, vol. 149, no. 4, pp. 675–680, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Xue, K.-J. Chen, and H.-J. Yin, “Relationship between polymorphism of platelet membrane glycoprotein III a and coronary heart disease with blood-stasis syndrome in Chinese Han population,” Zhong Xi Yi Jie He Xue Bao, vol. 7, no. 4, pp. 325–329, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. F. Liao, “Herbs of activating blood circulation to remove blood stasis,” Clinical Hemorheology and Microcirculation, vol. 23, no. 2-4, pp. 127–131, 2000. View at Google Scholar · View at Scopus
  14. Chinese Society of Cardiology, “Guidelines for the diagnosis and management of patients with chronic stable angina,” Chinese Journal of Cardiology, vol. 35, no. 3, pp. 159–206, 2007. View at Google Scholar
  15. Cardiovascular Specialty Committee and China Association of Integrative Medicine, “Criterion of syndrome differentiation for CHD,” Zhong Guo Zhong Xi Yi Jie He Za Zhi, vol. 11, p. 257, 1991. View at Google Scholar
  16. J. Wang, Study on Diagnostic Criteria of Blood Stasis Syndrome, United Publishing House of Beijing Medical University and Chinese Union Medical University, Beijing, China, 1993.
  17. Y. Yan, H. M. Tang, Y. Rao et al., “Fingerprint analysis of xuefuzhuyu oral liquid by high performance liquid chromatography,” Chinese Traditional and Herbal Drugs, vol. 4, no. 40, pp. 566–568, 2009. View at Google Scholar
  18. M. Xue, K. J. Chen, and H. J. Yin, “Association between platelet membrane glycoprotein IIb polymorphism and coronary heart disease in Han people,” Zhong Guo Bing Li Sheng Li Za Zhi, vol. 25, no. 10, pp. 1898–1902, 2009. View at Google Scholar
  19. Antithrombotic Trialists' Collaboration, “Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients,” British Medical Journal, vol. 324, no. 7329, pp. 71–86, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Patrono, B. Coller, J. E. Dalen et al., “Platelet-active drugs: the relationships among dose, effectiveness, and side effects,” Chest, vol. 119, no. 1, supplement, pp. 39S–63S, 2001. View at Google Scholar · View at Scopus
  21. J. W. Eikelboom, J. Hirsh, J. I. Weitz, M. Johnston, Q. Yi, and S. Yusuf, “Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events,” Circulation, vol. 105, no. 14, pp. 1650–1655, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. L. Cañivano Petreñas and C. García Yubero, “Resistance to aspirin: prevalence, mechanisms of action and association with thromboembolic events. A narrative review,” Farmacia Hospitalaria, vol. 34, no. 1, pp. 32–43, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. C. H. Hennekens, O. Sechenova, D. Hollar, and V. L. Serebruany, “Dose of aspirin in the treatment and prevention of cardiovascular disease: current and future directions,” Journal of Cardiovascular Pharmacology and Therapeutics, vol. 11, no. 3, pp. 170–176, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. R. Mehran, U. Baber, P. G. Steg et al., “Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study,” The Lancet, vol. 382, no. 9906, pp. 1714–1722, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. W. Liu, E. M. Poole, C. M. Ulrich, and R. J. Kulmacz, “Decreased cyclooxygenase inhibition by aspirin in polymorphic variants of human prostaglandin H synthase-1,” Pharmacogenetics and Genomics, vol. 22, no. 7, pp. 525–537, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. M. de Vita, V. Coluccia, F. Burzotta, E. Romagnoli, and C. Trani, “Intracoronary use of GP IIb/IIIa inhibitors in percutaneous coronary interventions,” Current Vascular Pharmacology, vol. 10, no. 4, pp. 448–453, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. M.-P. Li, Y. Xiong, A. Xu et al., “Association of platelet ITGA2B and ITGB3 polymorphisms with ex vivo antiplatelet effect of ticagrelor in healthy Chinese male subjects,” International Journal of Hematology, vol. 99, no. 3, pp. 263–271, 2014. View at Publisher · View at Google Scholar · View at Scopus